|Support type:||Scholarships in Brazil - Doctorate|
|Effective date (Start):||March 01, 2010|
|Effective date (End):||November 30, 2012|
|Field of knowledge:||Biological Sciences - Pharmacology - Cardiorenal Pharmacology|
|Principal researcher:||Jose Eduardo Tanus dos Santos|
|Grantee:||Carla Speroni Ceron|
|Home Institution:||Faculdade de Medicina de Ribeirão Preto (FMRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil|
Hypertension is a serious clinical condition associated with a high mortality rate. The disease is accompanied by morphological and physiological changes of the cardiovascular system. The reactive oxygen species (ROS) and the extracellular matrix metalloproteinases (MMPs) participate in the development of these changes during hypertension. Among the drugs used in antihypertensive therapy are antagonists of beta-adrenergic receptors. There are three classes of these drugs, which differ by selectivity for beta-adrenergic receptors, lipid solubility and vasodilator actions of some drugs of the class. The antagonists of the beta-adrenergic receptors first and second generation also have adverse effects compared with those of the third generation. Nebivolol is a selective antagonist of the receptors ²1adrenérgicos third generation, which has vasodilating properties, antioxidant properties and is capable of stimulating production of nitric oxide (NO), independent of its effect ²1 receptor antagonist. As hypertension is an increase of ROS, the MMPs, endothelial dysfunction and vascular remodeling is possible that nebivolol, may prevent the increased levels of MMPs vascular dysfunction and vascular remodeling associated with 2K-1C hypertension independently of the ²1 receptor antagonism .